Literature DB >> 27044078

Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization.

Jordan R Willis1, Jessica A Finn2, Bryan Briney3, Gopal Sapparapu4, Vidisha Singh5, Hannah King5, Celia C LaBranche6, David C Montefiori6, Jens Meiler7, James E Crowe8.   

Abstract

Development of broadly neutralizing antibodies (bnAbs) against HIV-1 usually requires prolonged infection and induction of Abs with unusual features, such as long heavy-chain complementarity-determining region 3 (HCDR3) loops. Here we sought to determine whether the repertoires of HIV-1-naïve individuals contain Abs with long HCDR3 loops that could mediate HIV-1 neutralization. We interrogated at massive scale the structural properties of long Ab HCDR3 loops in HIV-1-naïve donors, searching for structured HCDR3s similar to those of the HIV-1 bnAb PG9. We determined the nucleotide sequences encoding 2.3 × 10(7)unique HCDR3 amino acid regions from 70 different HIV-1-naïve donors. Of the 26,917 HCDR3 loops with 30-amino acid length identified, we tested 30 for further study that were predicted to have PG9-like structure when chimerized onto PG9. Three of these 30 PG9 chimeras bound to the HIV-1 gp120 monomer, and two were neutralizing. In addition, we found 14 naturally occurring HCDR3 sequences that acquired the ability to bind to the HIV-1 gp120 monomer when adding 2- to 7-amino acid mutations via computational design. Of those 14 designed Abs, 8 neutralized HIV-1, with IC50values ranging from 0.7 to 98 µg/mL. These data suggest that the repertoire of HIV-1-naïve individuals contains rare B cells that encode HCDR3 loops that bind or neutralize HIV-1 when presented on a PG9 background with relatively few or no additional mutations. Long HCDR3 sequences are present in the HIV-naïve B-cell repertoire, suggesting that this class of bnAbs is a favorable target for rationally designed preventative vaccine efforts.

Entities:  

Keywords:  HIV; molecular conformation; neutralizing antibodies; protein design

Mesh:

Substances:

Year:  2016        PMID: 27044078      PMCID: PMC4843476          DOI: 10.1073/pnas.1518405113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Native protein sequences are close to optimal for their structures.

Authors:  B Kuhlman; D Baker
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

2.  Clustal W and Clustal X version 2.0.

Authors:  M A Larkin; G Blackshields; N P Brown; R Chenna; P A McGettigan; H McWilliam; F Valentin; I M Wallace; A Wilm; R Lopez; J D Thompson; T J Gibson; D G Higgins
Journal:  Bioinformatics       Date:  2007-09-10       Impact factor: 6.937

3.  Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

Authors:  J R Mascola; M G Lewis; G Stiegler; D Harris; T C VanCott; D Hayes; M K Louder; C R Brown; C V Sapan; S S Frankel; Y Lu; M L Robb; H Katinger; D L Birx
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Authors:  Ann J Hessell; Eva G Rakasz; David M Tehrani; Michael Huber; Kimberly L Weisgrau; Gary Landucci; Donald N Forthal; Wayne C Koff; Pascal Poignard; David I Watkins; Dennis R Burton
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

5.  Modeling structurally variable regions in homologous proteins with rosetta.

Authors:  Carol A Rohl; Charlie E M Strauss; Dylan Chivian; David Baker
Journal:  Proteins       Date:  2004-05-15

6.  Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Authors:  Melissa D Simek; Wasima Rida; Frances H Priddy; Pham Pung; Emily Carrow; Dagna S Laufer; Jennifer K Lehrman; Mark Boaz; Tony Tarragona-Fiol; George Miiro; Josephine Birungi; Anton Pozniak; Dale A McPhee; Olivier Manigart; Etienne Karita; André Inwoley; Walter Jaoko; Jack Dehovitz; Linda-Gail Bekker; Punnee Pitisuttithum; Robert Paris; Laura M Walker; Pascal Poignard; Terri Wrin; Patricia E Fast; Dennis R Burton; Wayne C Koff
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

7.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

8.  Very low affinity B cells form germinal centers, become memory B cells, and participate in secondary immune responses when higher affinity competition is reduced.

Authors:  Joseph M Dal Porto; Ann M Haberman; Garnett Kelsoe; Mark J Shlomchik
Journal:  J Exp Med       Date:  2002-05-06       Impact factor: 14.307

9.  Antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation.

Authors:  Didrik Paus; Tri Giang Phan; Tyani D Chan; Sandra Gardam; Antony Basten; Robert Brink
Journal:  J Exp Med       Date:  2006-04-10       Impact factor: 14.307

10.  Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Authors:  Ann J Hessell; Eva G Rakasz; Pascal Poignard; Lars Hangartner; Gary Landucci; Donald N Forthal; Wayne C Koff; David I Watkins; Dennis R Burton
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

View more
  14 in total

Review 1.  Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design.

Authors:  James E Crowe
Journal:  Cell Host Microbe       Date:  2017-08-09       Impact factor: 21.023

2.  Multiscale Methods in Drug Design Bridge Chemical and Biological Complexity in the Search for Cures.

Authors:  Rommie E Amaro; Adrian J Mulholland
Journal:  Nat Rev Chem       Date:  2018-04-11       Impact factor: 34.035

3.  Discovery of Marburg virus neutralizing antibodies from virus-naïve human antibody repertoires using large-scale structural predictions.

Authors:  Nina G Bozhanova; Amandeep K Sangha; Alexander M Sevy; Pavlo Gilchuk; Kai Huang; Rachel S Nargi; Joseph X Reidy; Andrew Trivette; Robert H Carnahan; Alexander Bukreyev; James E Crowe; Jens Meiler
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-23       Impact factor: 11.205

4.  How Germinal Centers Evolve Broadly Neutralizing Antibodies: the Breadth of the Follicular Helper T Cell Response.

Authors:  Rob J De Boer; Alan S Perelson
Journal:  J Virol       Date:  2017-10-27       Impact factor: 5.103

5.  Chemo-enzymatic Synthesis of N-glycans for Array Development and HIV Antibody Profiling.

Authors:  Sachin S Shivatare; Vidya S Shivatare; Chung-Yi Wu; Chi-Huey Wong
Journal:  J Vis Exp       Date:  2018-02-05       Impact factor: 1.355

Review 6.  Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.

Authors:  Laurent Verkoczy
Journal:  Adv Immunol       Date:  2017       Impact factor: 3.543

Review 7.  The expanding array of HIV broadly neutralizing antibodies.

Authors:  Laura E McCoy
Journal:  Retrovirology       Date:  2018-10-16       Impact factor: 4.602

8.  Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans.

Authors:  Nelson R Wu; Nathan I Nicely; Esther M Lee; Rachel K Reed; Brian E Watts; Fangping Cai; William E Walkowicz; Baptiste Aussedat; Julia A Jones; Amanda Eaton; Ashley M Trama; S Munir Alam; David C Montefiori; Barton F Haynes; Kevin O Saunders
Journal:  PLoS Pathog       Date:  2019-12-16       Impact factor: 6.823

9.  Memory B Cells that Cross-React with Group 1 and Group 2 Influenza A Viruses Are Abundant in Adult Human Repertoires.

Authors:  Kevin R McCarthy; Akiko Watanabe; Masayuki Kuraoka; Khoi T Do; Charles E McGee; Gregory D Sempowski; Thomas B Kepler; Aaron G Schmidt; Garnett Kelsoe; Stephen C Harrison
Journal:  Immunity       Date:  2018-01-16       Impact factor: 43.474

Review 10.  Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies.

Authors:  Christoph Kreer; Henning Gruell; Thierry Mora; Aleksandra M Walczak; Florian Klein
Journal:  Vaccines (Basel)       Date:  2020-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.